CytomX Therapeutics, Inc. Stock News

- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer - - Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC) expected in January 2027 - - Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study in 2L mCRC expected to be initiated by year-end - - Phase 1 Va...

- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H 2027 - SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced th...

Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - - Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing.

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Alejandra Carvajal as Chief Legal Officer.

SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Charles Fuchs, M.D., M.P.H., to its Board of Directors.

- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY ® and Regeneron's Veloci-Bi ® platforms -